Rachel B. Salit, H. Joachim Deeg

Slides:

Advertisements

Similar presentations

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,

How to Treat MDS without Stem Cell Transplantation

Advances in Biology, Diagnostics, and Treatment of Hodgkin’s Disease

Vikas Gupta, Jason Gotlib, Jerald P. Radich, Nicolaus M

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia Katerina Ancevski,

Allogeneic Stem Cell Transplantation in Myelofibrosis

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Sabina Kersting, Leo F. Verdonck

Eltrombopag Eliminates Transfusion Requirements in a Patient with Fanconi Anemia Ashish Gupta, MD, MPH, Rasmi Palassery, MD, Sanjay Ahuja, MD, MBA, Rachel.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Caroline F. Morrison, Donna M

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children Coco de Koning, Maud Plantinga, Paul Besseling, Jaap Jan Boelens,

Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

J. J. Nietfeld, Marcelo C. Pasquini, Brent R

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation Filippo Milano, Margaret A. Au,

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage.

Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups H. Joachim Deeg, Christopher.

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia Daniella.

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

Infection Prevention - Visitors and the Best of Intentions

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Pretransplant Neutropenia Is Associated with Poor-Risk Cytogenetic Features and Increased Infection-Related Mortality in Patients with Myelodysplastic.

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Stratification of Allogeneic Hematopoietic Cell Transplant Patients by Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score

Steven M. Trifilio, Judy Pi, Jayesh Mehta

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

Development of an Assessment Tool for Patient Evaluation Prior to Hematopoietic Stem Cell Transplantation (HSCT) Jaskiran Kaur, Madhu Ragupathi, Eric.

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation

Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation Stefan O. Ciurea, Marcos de Lima, Sergio Giralt, Rima Saliba, Carlos.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives Minakshi Raj, Sung Won Choi,

Blood and Marrow Transplant Handbook

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Mammen Chandy Biology of Blood and Marrow Transplantation

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.

Treatment versus Transplant for Challenging Hematologic Disorders

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

Experiences and Decision Making in Hematopoietic Stem Cell Transplant in Sickle Cell Disease: Patients' and Caregivers' Perspectives Kirshma Khemani,

Presentation transcript:

Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge? Rachel B. Salit, H. Joachim Deeg Biology of Blood and Marrow Transplantation Volume 24, Issue 4, Pages 649-658 (April 2018) DOI: 10.1016/j.bbmt.2017.10.037 Copyright © 2018 Terms and Conditions

Figure 1 Five parameters are scored in the DIPSS [7]. Three additional factors are added in the DIPSS plus [6]. The final score in the DIPSS plus is composed of the value assigned to the DIPSS risk categories (0, 1, 2, or 3) plus the points added from the 3 DIPSS plus factors. Adverse karyotypes include +8,-5/del5q,-7/del7q,i(17q), inv(3),11q23 rearrangements. Biology of Blood and Marrow Transplantation 2018 24, 649-658DOI: (10.1016/j.bbmt.2017.10.037) Copyright © 2018 Terms and Conditions